AVNET, SOFIA
 Distribuzione geografica
Continente #
NA - Nord America 8.047
AS - Asia 7.677
EU - Europa 5.428
SA - Sud America 447
AF - Africa 403
OC - Oceania 52
Continente sconosciuto - Info sul continente non disponibili 1
Totale 22.055
Nazione #
US - Stati Uniti d'America 7.798
CN - Cina 2.454
SG - Singapore 1.945
VN - Vietnam 1.542
GB - Regno Unito 1.227
DE - Germania 870
IT - Italia 858
HK - Hong Kong 572
SE - Svezia 536
FR - Francia 353
IN - India 329
BR - Brasile 307
RU - Federazione Russa 263
NL - Olanda 243
KR - Corea 218
UA - Ucraina 209
CA - Canada 207
JP - Giappone 190
IE - Irlanda 188
FI - Finlandia 151
ZA - Sudafrica 132
AT - Austria 106
CI - Costa d'Avorio 106
BD - Bangladesh 80
CH - Svizzera 74
TG - Togo 70
EE - Estonia 65
BG - Bulgaria 57
AR - Argentina 55
SC - Seychelles 50
AU - Australia 49
IL - Israele 45
ID - Indonesia 42
BE - Belgio 41
PL - Polonia 39
JO - Giordania 36
ES - Italia 35
PH - Filippine 34
PK - Pakistan 31
TR - Turchia 27
GR - Grecia 23
IQ - Iraq 23
MX - Messico 23
TH - Thailandia 21
EC - Ecuador 20
LT - Lituania 18
TW - Taiwan 16
CL - Cile 15
PT - Portogallo 15
EG - Egitto 12
NO - Norvegia 12
PE - Perù 12
CO - Colombia 11
VE - Venezuela 11
MY - Malesia 9
PY - Paraguay 9
SA - Arabia Saudita 9
AE - Emirati Arabi Uniti 8
AL - Albania 8
UZ - Uzbekistan 8
CZ - Repubblica Ceca 6
DK - Danimarca 6
HU - Ungheria 6
LB - Libano 6
MA - Marocco 6
NG - Nigeria 6
HR - Croazia 5
IR - Iran 5
KE - Kenya 5
KZ - Kazakistan 5
QA - Qatar 5
RO - Romania 5
DO - Repubblica Dominicana 4
UY - Uruguay 4
BO - Bolivia 3
ET - Etiopia 3
HN - Honduras 3
LK - Sri Lanka 3
NZ - Nuova Zelanda 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
DZ - Algeria 2
GE - Georgia 2
GH - Ghana 2
GT - Guatemala 2
NP - Nepal 2
PA - Panama 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RS - Serbia 2
SV - El Salvador 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
Totale 22.043
Città #
Singapore 1.358
Southend 816
Ashburn 759
Fairfield 600
Chandler 535
Hong Kong 487
Hefei 470
Santa Clara 461
San Jose 346
Woodbridge 314
Ho Chi Minh City 313
Wilmington 298
Seattle 286
Ann Arbor 280
Houston 275
Hanoi 263
Princeton 238
Beijing 234
Dong Ket 212
Los Angeles 207
Cambridge 201
Seoul 184
Dublin 181
Tokyo 162
Boardman 161
Bologna 151
Nanjing 133
Jacksonville 132
Council Bluffs 127
Lauterbourg 124
Munich 119
Helsinki 111
Dallas 110
Abidjan 106
Berlin 91
Westminster 86
New York 81
Padova 79
Mcallen 77
Guangzhou 74
Montréal 74
Lomé 70
Boston 68
Vienna 67
Frankfurt am Main 65
Bern 63
Shanghai 59
Buffalo 58
Haiphong 57
Jinan 55
Saint Petersburg 55
San Diego 52
Sofia 52
Da Nang 51
Tianjin 50
Johannesburg 49
Milan 49
Shenyang 44
Bengaluru 43
Redondo Beach 39
Tuscaloosa 39
Toronto 38
Chicago 37
Florence 37
Hangzhou 37
Ypsilanti 37
Amman 36
Ottawa 35
Washington 35
Windsor 35
Brussels 34
Hebei 34
Zhengzhou 34
Medford 31
Changchun 30
Irvine 30
Nanchang 30
Nuremberg 30
Turin 30
London 29
Mülheim 29
Bremen 27
Changsha 26
Des Moines 26
Jakarta 26
Jerusalem 26
Porto Alegre 26
Warsaw 26
Wuhan 26
Ha Kwai Chung 25
Brisbane 24
Phoenix 23
São Paulo 22
Falkenstein 21
Fuzhou 21
Paris 20
Raleigh 20
Amsterdam 19
Chennai 19
Shenzhen 19
Totale 13.511
Nome #
The human tumor microbiome is composed of tumor type-specific intracellular bacteria 2.280
Validation of Suitable Housekeeping Genes for the Normalization of mRNA Expression for Studying Tumor Acidosis 578
V-ATPase is a candidate therapeutic target for Ewing sarcoma 277
Abstract 5909: IDH mutations in G2-3 conventional chondrosarcoma of bone: a mono institutional experience 274
A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE conjugate. 254
V-ATPase as an effective therapeutic target for sarcomas. 244
Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance 238
Exosome-like Nanovesicles Isolated from Citrus limon L. Exert Antioxidative Effect 227
Acid microenvironment promotes cell survival of human bone sarcoma through the activation of cIAP proteins and NF-κB pathway 226
Benign albeit glycolytic: MCT4 expression and lactate release in giant cell tumour of bone 223
In vitro blockade of Receptor Activator of Nuclear factor kappa b ligand prevents osteoclastogenesis induced by neuroblastoma cells 216
Acid-Induced Inflammatory Cytokines in Osteoblasts: A Guided Path to Osteolysis in Bone Metastasis 214
IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience 213
Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate 212
Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. 209
Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation 203
Cause and effect of microenvironmental acidosis on bone metastases 201
Uncovering the protective role of lipid droplet accumulation against acid-induced oxidative stress and cell death in osteosarcoma 199
Strawberry-derived exosome-like nanoparticles prevent oxidative stress in human mesenchymal stromal cells 198
Prominent role of RAB39A-RXRB axis in cancer development and stemness 197
Incorporation/Enrichment of 3D Bioprinted Constructs by Biomimetic Nanoparticles: Tuning Printability and Cell Behavior in Bone Models 193
The Role of Autophagy in the Maintenance of Stemness and Differentiation of Mesenchymal Stem Cells 191
Osteoblasts from a mandibuloacral dysplasia patient induce human blood precursors to differentiate into active osteoclasts. 190
Bone on-a-chip: a 3D dendritic network in a screening platform for osteocyte-targeted drugs 188
Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment 188
Identification and validation of housekeeping genes for gene expression analysis of cancer stem cells 187
Endogenous extracellular matrix regulates the response of osteosarcoma 3D spheroids to doxorubicin 185
New advances in the study of bone tumors: A lesson from the 3D environment 184
MDA-MB-231 breast cancer cells fuel osteoclast metabolism and activity: A new rationale for the pathogenesis of osteolytic bone metastases 181
Impairment of lysosomal activity as a therapeutic modality targeting cancer stem cells of embryonal rhabdomyosarcoma cell line RD. 180
Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Cancer Metabolism 180
Exploring metabolic adaptations to the acidic microenvironment of osteosarcoma cells unveils sphingosine 1-phosphate as a valuable therapeutic target 180
Contribution of mitochondrial activity to doxorubicin-resistance in osteosarcoma cells 178
Histogenetic characterization of giant cell tumor of bone 177
Spheroid-based 3D cell cultures identify salinomycin as a promising drug for the treatment of chondrosarcoma 177
Tumor-activated mesenchymal stromal cells promote osteosarcoma stemness and migratory potential via IL-6 secretion 177
The effect of extracellular acidosis on the behaviour of mesenchymal stem cells in vitro 177
The Effects of Systemic and Local Acidosis on Insulin Resistance and Signaling 176
3d printing and bioprinting to model bone cancer: The role of materials and nanoscale cues in directing cell behavior 176
FT-IR Spectral Signature of Sensitive and Multidrug-Resistant Osteosarcoma Cell-Derived Extracellular Nanovesicles 175
Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. 175
Molecular basis of osteoclastogenesis induced by osteoblasts exposed to wear particles 175
Increased osteoclast activity is associated with aggressiveness of osteosarcoma. 175
Acid microenvironment in bone sarcomas 172
In vitro study of human osteoclast activity on poli(epsilon-caprolactone) as a bone substitute biomaterial 170
Cathepsin k antisense inhibition of cell polarization and bone resorption in human osteoclast 169
Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells 168
Energy metabolism in osteoclast formation and activity 166
The influence of alumina and ultra-high molecular weight polyethylene particles on osteoblast-osteoclast cooperation 165
In vitro effects of an antisense oligonucleotide targeting fgf-2 on renal carcinoma cells metastasizing to bone 164
Primitive and bone metastatic renal carcinoma cells promote osteoclastogenesis through endothelial cells 163
Insulin receptor isoforms are differently expressed during human osteoblastogenesis. 163
Mesenchymal stromal cell adhesion and proliferation on ion-irradiated and RGD-modified polymer substrates 162
Pre-clinical Models for Studying the Interaction between Mesenchymal Stromal Cells and Cancer Cells and the Induction of Stemness 162
Electrospun fibers coated with nanostructured biomimetic hydroxyapatite: A new platform for regeneration at the bone interfaces 161
Elevated serum activity of TRACP5B in osteosarcoma patients (OS) is associated with an aggressive phenotype and with OS induced osteoclast activity 159
Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. 158
Curcumin-loaded nanoparticles impair the pro-tumor activity of acid-stressed msc in an in vitro model of osteosarcoma 157
Mesenchymal Stem Cells-Derived Small Extracellular Vesicles and Their Validation as a Promising Treatment for Chondrosarcoma in a 3D Model in Vitro 156
Effects of prelamin A processing inhibitors on the differentiation and activity of human osteoclasts. 155
Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. 155
A Novel Microfluidic Platform for Personalized Anticancer Drug Screening Through Image Analysis 154
Osteoclast differentiation from human blood precursors on biomimetic calcium-phosphate substrates 153
Metabolism and microenvironment in cancer plasticity 153
Antagonizing the S1P-S1P3 Axis as a Promising Anti-Angiogenic Strategy 152
Sphere-forming cell subsets with cancer stem cell properties in human musculoskeletal sarcomas 152
Mesenchymal stroma: Role in osteosarcoma progression 151
Automated Detection of Spinal Lesions From CT Scans via Deep Transfer Learning 150
Serum markers of loosening in patients with THA 149
Annual meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic networks in cancer 149
The Effect of Poly(d,l-Lactide-co-Glycolide)-Alendronate Conjugate Nanoparticles on Human Osteoclast Precursors. 148
Platelet-rich plasma impairs osteoclast generation from human precursors of peripheral blood. 148
Role of IGF-IR in osteoclast biology and differentiation 147
Height and pathogenesis of osteosarcoma 147
Radiodynamic Therapy with Acridine Orange Is an Effective Treatment for Bone Metastases 146
Oct-1 recruitment to the nuclear envelope in adult-onset autosomal dominant leukodystrophy. 146
Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Adaptations and Targets in Cancer 145
Sarcoma treatment in the era of molecular medicine 145
Individual Trajectories of Bone Mineral Density Reveal Persistent Bone Loss in Bone Sarcoma Patients: A Retrospective Study 143
Spontaneous Formation of Multinucleated Giant Cells with Bone Resorbing Activity by Long Culture of Human Peripheral Blood CD14-Positive Monocytes In Vitro. 141
in vitro effects of interferon-alpha on different cellular elements existing in a bone metastasis of renal cell carcinoma 138
Stromal cells derived from giant cell tumor of bone show osteoblast-like feature 138
Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. 138
Cytoskeletal disorganization in human osteoclasts following cathepsin K down-regulation 137
Photodynamic Surgery for Feline Injection-Site Sarcoma 135
Therapeutic implications of tumor interstitial acidification 134
The release of inflammatory mediators from acid-stimulated mesenchymal stromal cells favours tumour invasiveness and metastasis in osteosarcoma 134
Potential role of tartrate-resistant acid phosphatase 5b (TRACP 5b) as a surrogate marker of late loosening in patients with total hip arthroplasty: A cohort study. 132
IGF2 derived from SH-SY5Y neuroblastoma cells induces the osteoclastogenesis of human monocytic precursors. 131
Perfused Platforms to Mimic Bone Microenvironment at the Macro/Milli/Microscale: Pros and Cons 131
Bond Strength and Ultramorphological Evaluation After Simplified Immediate Dentin Sealing 129
Study on the in vitro effect of platelet rich plasma on bone endothelial cells and on osteoclast differentiation for maxillo-facial surgery 129
Unravelling the Effect of Citrate on the Features and Biocompatibility of Magnesium Phosphate-Based Bone Cements 129
Behavioral Voluntary and Social Bioassays Enabling Identification of Complex and Sex-Dependent Pain-(-Related) Phenotypes in Rats with Bone Cancer 128
Role of Pericellular Matrix in the Regulation of Cancer Stemness 127
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 126
Epigenetic Regulation Mediated by Sphingolipids in Cancer 125
The natural compound Alizarin as an osteotropic drug for the treatment of bone tumors. 125
Sustained Autocrine Induction and Impaired Negative Feedback of Osteoclastogenesis in CD14(+) Cells of Giant Cell Tumor of Bone 125
Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells 124
Totale 19.407
Categoria #
all - tutte 58.109
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.109


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021457 0 0 0 0 0 0 0 0 0 0 0 457
2021/20222.258 200 84 147 165 158 123 58 153 78 237 463 392
2022/20232.358 244 341 129 265 177 177 69 152 371 55 202 176
2023/2024659 81 111 57 51 50 131 27 33 16 54 31 17
2024/20253.187 90 438 216 248 566 199 155 115 30 287 214 629
2025/20268.989 649 745 693 624 1.171 606 953 494 1.692 725 406 231
Totale 22.516